Patients with a diagnosis of major depressive disorder (MDD)or schizophrenia Mental and Behavioural Disorders
Conditions
Interventions
This is a prospective cohort study to evaluate the effectiveness and clinical utility of the PGx testing in enhancing
medication safety and tolerability in 150 Arab patients diagnosed with MDD and sch
Sponsors
Qatar Precision Health Institute (QPHI)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Adult of age 18-65 2. Arab origin: This study focuses on identifying genetic variants and their clinical implications specific to the Arab population. Inclusion of only Arab participants minimizes genetic heterogeneity, ensuring valid, population-specific findings that can directly inform precision medicine initiatives for this community. We identify the Arab population based on their nationality following the QBB protocol. 3. Those who are diagnosed with MDD or Schizophrenia (new and previously diagnosed) or other related psychotic or mood disorders based on clinical Judgment 4. Those who are eligible for prescription of psychotropic medications 5. Provide a written consent for participation
Exclusion criteria
Exclusion criteria: 1. Current diagnosis of delirium 2. Current diagnosis of dementia 3. High suicide risk 4. Current diagnosis of amnestic 5. Current diagnosis of another cognitive disorder 6. Current diagnosis of an eating disorder 7. Participated in a clinical trial within the past month 8. Other acute serious psychiatric disorder other than depression and schizophrenia 9. Excessive consumption of alcohol and/or drugs 10. Severe acute or severe chronic somatic diseases 11. Pregnant or lactating women 12. Patients with a severe cognitive impairment, which affects adherence to therapy or the ability to sign the consent form 13. Patients with active cancers 14. Having renal failure or severe renal dysfunction identified by a glomerular filtration rate of less than 30 ml/min/1.73 m2 15. Having severe hepatic dysfunction defined by raised serum aminotransferase (x 3 folds of normal levels) and hospitalized for hepatic disease 16. Patients with cardiac dysfunction defined by reduced left ventricular ejection fraction (LVEF less than 35) or significant QTc-interval prolongation more than 500
Countries
Qatar
Contacts
Public ContactWadha Al Muftah
Outcome results
None listed